Menu

Biosimilars/Research

Etanercept V14H14

Clinical trials for etanercept biosimilars

Biosimilars/Research | Posted 22/05/2015

Researchers from the Charité – Universitätsmedizin Berlin, Germany, carried out a systematic review into clinical trials for etanercept biosimilars as part of their investigation into biosimilars for the treatment of psoriasis [1].

Clinical Trials 2 V13K29

Clinical trials for infliximab biosimilars

Biosimilars/Research | Posted 29/05/2015

A systematic review into clinical trials for infliximab biosimilars was carried out as part of an investigation into biosimilars for the treatment of psoriasis by researchers from the Charité – Universitätsmedizin Berlin, Germany [1].

Biosimilars V13E10

Incomplete processing in recombinant streptokinase

Biosimilars/Research | Posted 29/05/2015

A study investigating the impact of incomplete processing on streptokinase activity has found that ‘similar biologics’ or different batches of the biological may have different potencies, depending on the degree of amino-terminal methionine processing and on the pharmacopoeial assay method used, affecting the dosage patients receive [1].

DNA Kaku V13C15

Variation in recombinant streptokinase

Biosimilars/Research | Posted 22/05/2015

A study of blood clot dissolving drug streptokinase has highlighted the mantra of ‘the process is the product’ in the case of biologicals [1].

Adalimumab V13F21

Clinical trials for adalimumab biosimilars

Biosimilars/Research | Posted 15/05/2015

As part of their investigation into biosimilars for the treatment of psoriasis, researchers from the Charité – Universitätsmedizin Berlin, Germany, carried out a systematic review into clinical trials for adalimumab biosimilars [1].

Substitution V13F14

Biosimilar filgrastim highly similar to originator filgrastim

Biosimilars/Research | Posted 08/05/2015

A study comparing Sandoz’s filgrastim biosimilar (Zarzio) with originator filgrastim (Neupogen) has shown that they are highly similar in terms of their structure and function [1].

Clinical Trials 2 V13K29

Clinical trials of biosimilars for psoriasis treatment

Biosimilars/Research | Posted 08/05/2015

Tumour necrosis factor-alpha (TNF-alpha) is a cytokine, or protein, that prompts the body to create inflammation. In psoriasis and psoriatic arthritis, there is excess production of TNF-alpha in the skin or joints. Therefore, drugs that block TNF-alpha, such as Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab) and Stelara (ustekinumab), can be used to treat psoriasis and psoriatic arthritis.

ANDA Approval V13F21

Considerations when promoting generics prescribing in the US

Biosimilars/Research | Posted 04/05/2015

Sarpatwari and co-authors investigate the legal and ethical consideration for promoting generics prescribing in the US and how this might apply to biosimilars [1].

Clinical Trials V13F14

Adalimumab biosimilar meets primary endpoints in phase I study

Biosimilars/Research | Posted 04/05/2015

US biotech company Oncobiologics announced on 12 February 2015 that ONS-3010, its adalimumab biosimilar candidate, met the primary endpoints in its first clinical study.

05 AA011027

Promoting generics prescribing in the US

Biosimilars/Research | Posted 27/04/2015

Sarpatwari and co-authors discuss physician-centered strategies used to promote generics prescribing in the US and how such strategies might apply to biosimilars [1].